Literature DB >> 2858937

Nesidioblastosis and intermediate cells in the pancreas of patients with hyperinsulinemic hypoglycemia.

D Bani, T Bani Sacchi, G Biliotti.   

Abstract

The pancreases of three patients with hyperinsulinemic hypoglycemia were studied: one of these patients was a child born to a diabetic mother, the other two were adults with insulinomas. All the patients had nesidioblastosis, namely the presence of a number of pancreatic endocrine cells spread throughout the exocrine tissue singly or clustered in small groups. In the hypoglycemic child the endocrine cells scattered in the acinar tissue were mostly A cells, whereas in the patients with insulinomas both A and B cells were found with a similar frequency. Intermediate cells (acinar-islet cells) were found in all the cases. These findings suggest that nesidioblastosis and the de novo formation of intermediate cells are associated phenomena. Possible mechanisms for the genesis of the islet cell types spread throughout the exocrine parenchyma and of the intermediate cells are discussed and their possible clinical implications are suggested.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2858937     DOI: 10.1007/bf02890112

Source DB:  PubMed          Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol        ISSN: 0340-6075


  3 in total

Review 1.  Adult nesidioblastosis: a case report and review of the literature.

Authors:  R D Rinker; K Friday; F Aydin; B M Jaffe; L Lambiase
Journal:  Dig Dis Sci       Date:  1998-08       Impact factor: 3.199

2.  Persistent hyperinsulinemic hypoglycemia of infancy: constitutive activation of the mTOR pathway with associated exocrine-islet transdifferentiation and therapeutic implications.

Authors:  Sanda Alexandrescu; Nina Tatevian; Oluyinka Olutoye; Robert E Brown
Journal:  Int J Clin Exp Pathol       Date:  2010-08-08

3.  Ontogeny, postnatal development and ageing of endocrine pancreas in Bubalus bubalis.

Authors:  C Lucini; L Castaldo; O Lai; G De Vico
Journal:  J Anat       Date:  1998-04       Impact factor: 2.610

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.